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Edited by Takashi GojoboriAbstract Breast cancer is the most common cancer in women
worldwide. To identify novel amplicons involved in the mammary
carcinogenesis, we constructed gene expression maps of chromo-
somes in 35 human breast cancer cell lines and extracted six can-
didate amplicons containing highly expressed gene clusters on
chromosomes 8, 17, and X. We also conﬁrmed the presence of
the identiﬁed amplicons in clinical specimens by Southern blot
analysis. Highly expressed genes identiﬁed in the amplicons will
contribute to the characterization of breast cancer phenotypes,
thereby providing novel targets for anticancer therapies.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cytogenetic and molecular studies on breast cancer have fre-
quently identiﬁed imbalanced chromosomal regions. Several
amplicons and candidate genes have been identiﬁed therein,
including 8q24 (MYC); 8p11-12 (SPFH2, BRF2, and RAB11-
FIP1); 11q13 (CCND1, CTTN [EMS1], C11orf30 [EMSY],
PAK1, and THRSP); 12q13 (MDM2); 17q12-21 (ERBB2);
17q23 (RPS6KB1, TRIM37 [MUL], APPBP2, THRAP1
[TRAP240], RAD51C, and BCAS3); and 20q11-q13 (NCOA3
[AIB1], AURKA [BTAK], BCAS1 [NABC1], ZNF217, and
BCAS4) [1–3]. One of the best-characterized genes that are
ampliﬁed in breast cancer is the ERBB2 (HER2/NEU) gene,
a member of the epidermal growth factor receptor family.
Overexpression of ERBB2 due to gene ampliﬁcation is ob-
served in almost 30% of breast cancers, and ERBB2 has beenAbbreviations: CGH, comparative genomic hybridization
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doi:10.1016/j.febslet.2007.07.016used as a diagnostic marker and an indicator of poor prognosis
in breast cancer [4–7]. ERBB2 is also a clinically relevant target
for the treatment of breast cancer. Therapy with humanized
monoclonal antibodies against ERBB2 (Herceptin, Genen-
tech, Inc.), either alone or in combination with conventional
chemotherapeutic agents, is eﬀective against a subset of
ERBB2-overexpressing breast cancers [8,9]. Thus, it is biolog-
ically and clinically important to identify genomic alterations
in tumors and study the functions of the genes involved. Re-
cent microarray-based comparative genomic hybridization
(CGH) combined with expression analysis has accelerated
the identiﬁcation of novel amplicons and candidate genes,
some of which have been found to be associated with tumori-
genesis [3,10–12]. In this study, we describe novel amplicon
candidates that were explored using gene expression proﬁles
obtained from breast cancer cell lines and whose presence
was conﬁrmed in clinical specimens.2. Materials and methods
2.1. Cell lines
Human breast cancer cell lines were obtained from the Cell Resource
Center for Biomedical Research, Tohoku University (CRL1500,
MCF7, SK-BR-3, and YMB-1-E), and purchased from the American
Type Culture Collection (ATCC) (Rockville, MD, USA; http://www.
atcc.org/) (BT-20, BT-474, BT-483, BT-549, CAMA-1, DU4475,
HCC1143, HCC1395, HCC1419, HCC1500, HCC1937, HCC1954,
HCC202, HCC2157, HCC2218, HCC38, HCC70, Hs 578T, MDA-
MB-134VI, MDA-MB-157, MDA-MB-175VII, MDA-MB-231,
MDA-MB-361, MDA-MB-415, MDA-MB-436, MDA-MB-453,
MDA-MB-468, T-47D, UACC-812, UACC-893, and ZR-75-30). All
cell lines were cultured according to the recommendations of the
supplier.
2.2. Microarray analysis
Synthetic polynucleotides (80-mers) representing 30913 species of
human transcripts (MicroDiagnostic, Tokyo, Japan) were arrayed by
using a custom arrayer. Poly(A)+ RNA was extracted from cells har-
vested at approximately 70% conﬂuency after incubation in fresh med-
ia for 16 h. Two micrograms of poly(A)+ RNA was labeled with
Cyanine 5-dUTP or Cyanine 3-dUTP (PerkinElmer, MA, USA). Hu-
man common reference RNA was prepared by mixing equal amounts
of poly(A)+ RNA extracted from 22 human cancer cell lines to reduceblished by Elsevier B.V. All rights reserved.
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with a labeling and hybridization kit (MicroDiagnostic). Signals were
measured with a GenePix 4000A scanner (Axon Instruments Inc., CA,
USA) and then processed into primary expression ratios (ratio of the
Cyanine-5 intensity of each cell line to the Cyanine-3 intensity of the
human common reference RNA). Each ratio was normalized by mul-
tiplication with the normalization factors using the Gene Pix Pro 3.0
software (Axon Instruments Inc.). The primary expression ratios were
converted into log2 values (designated log ratios). The mean average
log ratio of 35 cancer cell lines was calculated for each transcript; this
was then subtracted from the log ratio for each transcript (designated
subtracted log ratio). The subtracted log ratios were used as the ﬁnal
data for subsequent amplicon analysis (Supplementary Table 1). We
assigned an expression ratio of 1 (log ratio of 0) for spots that exhibited
ﬂuorescence intensities under the detection limits, and we did not in-
clude these in the signal calculation of the mean averages and sub-
tracted log ratios. The data were processed using Microsoft Excel
software (Microsoft). In accordance with the Minimum Information
about a Microarray experiment (MIAME) guideline, all the data were
deposited at the DNA Data Bank of Japan (DDBJ) via the Center for
Information Biology gene EXpression (CIBEX) database (http://ci-
bex.nig.ac.jp/index.jsp) under the accession number CBX20.
2.3. Construction of expression maps
Gene names, gene abbreviations, and accession numbers were ob-
tained from the Human Genome Organization (HUGO) Gene
Nomenclature Committee (http://www.gene.ucl.ac.uk/nomenclature/
index.html) [14]; information for gene localization on chromosomes
was acquired from GeneLoc (http://genecards.weizmann.ac.il/geneloc)
[15]. From a total of 30913 species of transcripts on the microarrays,
we generated high-resolution expression maps based on the informa-
tion obtained for 17373 transcripts for which localization information
was available. For each chromosome of each cell line, the subtracted
log ratios were plotted on the vertical axis versus the initiation sites
of the transcripts on the horizontal axis.
2.4. Breast cancer DNA and Southern blot analysis
DNA samples extracted from the cell lines and tumor specimens
were subjected to standard Southern blot analysis. Human breast can-
cer specimens were obtained from the Dokkyo Medical University
Hospital. The ethics committee of the Dokkyo Medical University ap-
proved this study, and informed consent was obtained from all pa-
tients. Complementary DNA (cDNA) fragments for the probes were
ampliﬁed by PCR and they were then used directly or cloned intoChromosome 17
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Fig. 1. Mapping of gene expression data on chromosome 17. Eleven ‘‘amp
amplicons and one ‘‘amplicon-negative’’ cell line. The maximum values on
chromosomes, 79 Mb. The arrows indicate the amplicons: red, novel amplico
reported in other cancers previously; and blue, previously reported amplico
chromosome (see Supplementary Fig. 1 in terms of 23 other ‘‘amplicon-negpGEM-Teasy (Promega) for labeling. Information regarding each
probe is available from the corresponding author. Human DRG-1
cDNA at 22q12.2 was used as a control. The fragment size detected
by each probe was conﬁrmed by genomic information available at
http://www.ensembl.org/Homo_sapiens/index.html.3. Results and discussion
To explore gene clusters whose expression levels abnormally
increased in cancer based on analyses of gene expression pro-
ﬁles, we constructed an analytical system to identify such gene
clusters and validated this system on the basis of previously
identiﬁed gene clusters. Since elevated expression of ERBB2
and its neighboring genes in the chromosomal region of
17q12-21 has been extensively analyzed in breast cancer, we ﬁrst
focused on gene expression in chromosome 17 among the 35
breast cancer cell lines.We obtained the gene expression proﬁles
of these cell lines as ratios against the human common reference
RNA [13] (designated log ratios), extracted the expression data
for genes localized on chromosome 17, and assembled the data
according to the position on the chromosome to clarify the rela-
tionship between expression ratios and chromosomal positions.
Thereafter, to emphasize the presence of gene clusters with ele-
vated expression levels, we processed each log ratio of gene
expression into a log value relative to the mean average log ratio
of each gene among 35 proﬁles (designated subtracted log ra-
tios). Further, we plotted the subtracted log ratios on the verti-
cal axis and the initiation sites of the transcripts on the
horizontal axis (see Section 2 for calculation details). Fig. 1
shows that the subtracted log ratios of most transcripts are plot-
ted around the origin of the vertical axis (i.e., the mean average
log ratio). In contrast, several dots comprise spike-like clusters
with higher expression levels than the mean average for each
gene among the 35 cell lines. Among these spike-like clusters,
we conﬁrmed the presence of three amplicons previously identi-
ﬁed in breast cancer (Fig. 1, blue arrows): at 17q12-21, contain-HCC1419C202
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BR-3, UACC-812, UACC-893, and ZR-75-30 cells [16]; at
17q21-22, containing HOXB2, in HCC1419, HCC2218, and
ZR-75-30 cells [17]; and at 17q23, containing ribosomal protein
S6 kinase (RPS6KB1), in BT-474, HCC2218, and MCF-7 cells
[17].
Since we successfully observed previously identiﬁed ampli-
cons as spike-like clusters in the plots described above, we next
screened novel amplicon candidates under more precisely de-
ﬁned conditions with several parameters. Using conditions that
were satisﬁed by the previously identiﬁed amplicons, we deﬁned
the new screening condition as follows: (1) assigning a 0.5-Mbp
region for each transcript wherein its initiation site is centrally
localized; (2) extracting candidates in this assigned region,
which comprise clusters of transcripts with mean average sub-
tracted log ratios greater than 1.0; and (3) selecting the candi-
dates which contain at least 4 transcripts with subtracted log
ratios greater than 1.8. When multiple transcripts harbored
identical initiation sites, we selected a single representative tran-
script. Moreover, when the candidates comprised members of
identical gene families only, we abandoned these candidates
since an identical mechanism may modulate highly elevated
expression of such transcripts, irrespective of gene ampliﬁca-Fig. 2. Relative expression levels of genes localized in amplicon candidates d
the genes localized at 17p11 (A), 17q11 (B), 17q21 (C), and 17q25 (D) are rep
clusters shown in Fig. 1 as red or green arrows. Genes are aligned in order of
and blue indicate high and low expression levels relative to mean average log
changes in relative gene expression.tion. Our microarrays provided information of 11.9 transcripts
on average in each 0.5-Mbp region of chromosome 17; 2.2%
transcripts exhibited subtracted log ratios greater than 1.8
throughout chromosome 17. Eventually, on screening chromo-
some 17 under these conditions, we identiﬁed three novel ampli-
con candidates at 17q11 in ZR-75-30 cells; at 17q21 in BT-474,
HCC202, and HCC2218 cells; at 17q25 in HCC2218, MDA-
MB-453, and UACC893 cells (Fig. 1, red arrows). Moreover,
an amplicon candidate detected at 17p11 in HCC1419 cells,
containing SREBF1, has not been identiﬁed in breast cancer
so far but reported in leiomyosarcomas previously (Fig. 1, green
arrow) [18]. Fig. 2 shows detailed descriptions of subtracted log
ratio values for these amplicon candidates.
Since we successfully detected novel and previously identi-
ﬁed amplicons in chromosome 17, we extended the application
of the existing screening approach to chromosomes 8 and X,
and the results obtained are demonstrated in Fig. 3. In case
of chromosome 8 and X, 6.0 and 6.2 transcripts on average
are contained in each 0.5-Mbp region; 2.5% and 2.0% of tran-
scripts exhibited subtracted log ratios greater than 1.8, respec-
tively. By integrating gene expression information of each 0.5-
Mbp region, we identiﬁed three novel amplicon candidates at
8q13 in HCC2157 cells, at 8q21 in HCC1419 cells, and atetected in chromosome 17. Expression values (subtracted log ratios) of
resented in color. Cell lines depicted in red and green contain spike-like
chromosome location. In the color bar shown at the bottom right, red
ratio for each probe, respectively. Gradations of the two colors indicate
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amplicon candidate detected at 8p24.3 in HCC1419 cells, con-
taining RECQL4, has not been identiﬁed in breast cancer so
far but reported in metastasized colorectal cancers previously
(Fig. 3, green arrow) [19]. Additionally, we detected the follow-
ing previously identiﬁed amplicons: at 8p11, containing
SPFH2 (C8orf2), in BT-483, HCC1500, and MDA-MB-
134VI cells; at 8q24.13, speciﬁcally between EIF3S3 and
MYC, in SK-BR-3 cells; and at Xq28, speciﬁcally between
ARHGAP4 and CTAG2, in MDA-MB-453 cells (Fig. 3, blue
arrows) [1,2,20,21]. Fig. 4 shows detailed descriptions of sub-
tracted log ratio values for the novel amplicon candidates in
chromosomes 8 and X.
Subsequently, we investigated the novel amplicon candidates
detected in this study in chromosomes 8, 17, and X by using
Southern blot analyses with genomic DNA extracted from
the corresponding cell lines (Fig. 5). First, Southern blot anal-
yses with the probe SPFH2 within 8p11 and a previously iden-
tiﬁed amplicon revealed ampliﬁcation in the genomic DNA
extracted from BT-483, HCC1500, and MDA-MB-134VII;
this was entirely consistent with the results obtained on explor-
ing the gene expression proﬁles and previous reports[1,2].
Next, Southern blot analyses of the novel amplicon candidates
identiﬁed in this study were performed to examine ampliﬁca-
tion in each genomic region for the corresponding cell lines
as follows: the probe HCP1 for 17q11 in ZR-75-30 cells; the
probe EPN3 for 17q21 in BT-474, HCC202, and HCC2218
cells; the probe C17orf28 for 17q25 in MDA-MB-453 cells;
the probe SMC1L1 for Xp11 in HCC202 cells; the probe
LLGL2 for 17q25 in HCC2218 and UACC893 cells; and theprobe ZFAND1 for 8q21 in HCC1419 cells. We used two inde-
pendent probes for 17q25 since this region seemed to be di-
vided into two subregions: one containing C17orf28 and the
other containing LLGL2 (the interval between the initiation
sites of C17orf28 and LLGL2 was approximately 0.6 Mbp)
(Fig. 2D). Comparison of band intensities among cell lines
supported gene ampliﬁcation of these loci and proved reliabil-
ity of our screening algorithm (compare Fig. 5 with Figs. 1, 3
and supplementary Figs. 1–3).
Further, we tested whether such genomic ampliﬁcation was
present in breast cancer tissues. Initial Southern blot analyses
of DNA from 33 breast cancer tissues revealed that the regions
8q21 and 17q21 were signiﬁcantly ampliﬁed in one tumor spec-
imen from each breast cancer tissue, eliminating the possibility
that gene ampliﬁcation occurred during the establishment of
the cell lines (Fig. 6). In the present study, since the frequency
of ampliﬁcation and sample numbers were insuﬃcient, the
ampliﬁed regions were not statistically evaluated. Extensive
works of more clinical samples are required to elucidate the
signiﬁcance of the ampliﬁcation; nevertheless, maintenance of
the ampliﬁed regions may confer an evolutionary advantage
to cancers.
Of the ﬁve highly expressed genes at 8q21, ZFAND1 codes
for an uncharacterized protein with an AN1-type zinc ﬁnger
domain that is found in the DNA-binding, ATP-dependent
helicase protein SMUBP-2 (Fig. 4B). IMPA1 codes for inosi-
tol(myo)-1(or 4)-monophosphatase 1, which is involved in ino-
sitol phosphate metabolism. Epsin 3 encoded by EPN3 at
17q21 is localized speciﬁcally to migrating keratinocytes in
cutaneous wounds but is not found in intact skin, suggesting
Fig. 4. Relative expression levels of genes localized in amplicon
candidates detected in chromosomes 8 and X. Expression values
(subtracted log ratios) of the genes localized at 8q13 (A), 8q21 (B),
8q24.3 (C), and Xp11 (D) are represented in color. Cell lines depicted
in red and green contain spike-like clusters shown in Fig. 3 as red or
green arrows. Genes are aligned in order of chromosome location. For
color indications, refer to the legend for Fig. 2.
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Fig. 5. Southern blot analyses of genomic ampliﬁcation in breast
cancer cell lines. Five micrograms of genomic DNA was subjected to
Southern blot analyses. cDNA fragments for probes were ampliﬁed by
PCR and then cloned into pGEM-T easy (Promega) for labeling.
Information regarding each probe is available from the corresponding
author. Human DRG-1 cDNA was used as a control. The asterisk
depicts the cell line with conﬁrmed ampliﬁcation.
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Fig. 6. Southern blot analyses of genomic ampliﬁcation in breast
cancer specimens. Five micrograms of genomic DNA from tumor
tissues was subjected to Southern blot analysis. DRG1 probe was used
as a control. Each number (#1 to #25) indicates the patient code
number. Relative signal ratios, ZFAND1/DRG1 and EPN3/DRG1,
were calculated by normalizing the signal intensities of ZFAND1 and
EPN3 to that of DRG1 measured with a BAS2000 (FUJIFILM,
Japan). Human breast cancer specimens from tumors were obtained at
Dokkyo Medical University Hospital (Japan). The Ethics Committee
of Dokkyo Medical University approved this study, and informed
consent was obtained from all patients.
E. Ito et al. / FEBS Letters 581 (2007) 3909–3914 3913that EPN3 may function in activated epithelial cells during tis-
sue morphogenesis (Fig. 2C) [22]. ABCC3 codes for an ATP-
binding cassette subfamily C that is also known as multidrug
resistance-associated protein 3 (MRP3). MRP3 confers resis-
tance to etoposide and teniposide [23].
In the post-sequencing era, innovative tools are needed to
extract biologically signiﬁcant information from extensive gene
localization and expression data. Microarray-based CGH has
been widely used to detect imbalanced chromosomal regions
and has contributed to the identiﬁcation of novel oncogenes.
Although similar studies have been conducted extensively over
a long period [24,25], we successfully detected six novel ampli-
con candidates from only three chromosomes (8, 17, and X)
among 35 cell lines in addition to two amplicons previously re-
ported in other cancers but not yet identiﬁed in breast cancer
(summarized in Table 1). Our approach only requires a simple
comparison of an expression ratio obtained from each sample
with the mean average of the expression ratios across all sam-
ples for each gene. We think our method will be applicable
when enough number of samples that share common back-
ground are collected. Our system is expected to be useful also
for clinical specimen. Discovery of novel gene clusters with
aberrant expression levels and subsequent identiﬁcation of
Table 1
Summary of this study
Ch Probe Cell line Tissue
Map Southern Southern
8q13 MYBL1 HCC2157 ND ND
8q21 ZFAND1 HCC1419 Conﬁrmed 1/33
17q11 HCP1 ZR-75-30 Conﬁrmed 0/33
17q21 EPN3 BT-474 Conﬁrmed 1/33
HCC202 Conﬁrmed
HCC2218 Conﬁrmed
17q25 C17orf28 MDA-MB-453 Conﬁrmed ND
LLGL2 HCC2218 Conﬁrmed 0/33
UACC-893 Conﬁrmed
Xp11 SMC1L1 HCC202 Conﬁrmed 0/33
Ch, chromosome; ND, not done.
3914 E. Ito et al. / FEBS Letters 581 (2007) 3909–3914the genes responsible for cancer malignancy will provide tar-
gets for eﬃcacious anticancer therapies.
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